OVERVIEW OF NEW ANTI TB DRUGSAbstract
The emergence of multi-drug-resistant strains of M. tuberculosis makes it necessary for the discovery of new drugs, and also implement other modalities of treatment. Eperezolid and linezolid are oxalidinones which are in phase II clinical trials. Other oxalidinones like AZD5847 and PNU100480 are being evaluated in a phase I trials. Regimens based on a higher dose of rifampin in humans are also being evaluated. Rifapentine (10 mg/kg) was approved for the treatment of pulmonary TB in 1998. Fluroquinolones like Ofloxacin, Ciprofloxacin, Lomifloxacin, levofloxacin, sparfloxacin and Moxifloxacin are effective against M. tuberculosis and are in various phase of development. Newer molecules like TMC207, nitroimidazoles like PA-824 and OPC-67683 are in phase II. Diamines like SQ109 has shown to have in vitro action between SQ109 and isoniazid and especially rifampin. SQ609, a dipiperidine, which is an inhibitor of translocase, involved in cell wall synthesis, is in preclinical studies. Sudoterb (LL3858) is found to have bactericidal activity against both drug senstitive and MDR-TB. BTZ-043 (NM4TB Consortium), FAS20013, LL3858, CPZEN-45, are also in various stages of development. New potential drug molecules and drug targets are also being evaluated. New techniques like using FRIGATE, and Nanocarriers, chemical investigations on the whole plants Gentiana, methanolic root bark extract of Leucophyllum, Cinnamic derivatives are being evaluated for their role in anti TB activity. Immunomodulation with 1, 25-dihydoxyvitamin D and resection of cavitary or badly damaged lung tissue could be used as a adjuvant therapy in tuberculosis. Enumerous vaccines are in various stages of preclinical development.
P. Yadav*, P. Deolekar , V. Kanase and S. Mishra
Associate Professor in Pharmacology, Dr. D. Y. Patil Medical College, Navi Mumbai, Maharashtra, India
23 April, 2012
30 May, 2012
21 July, 2012
01 August, 2012